SUNNYSTRONG

Beijing Sunny Novo Pharmaceutical Research (Sunny Novo), often referred to by its brand name Sunnystrong, is a leading Chinese Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). The company provides a comprehensive suite of services across the entire drug development lifecycle, including drug discovery, preclinical research, clinical trial management (Phase I-IV), and CMC (Chemistry, Manufacturing, and Controls). Sunny Novo is particularly recognized for its expertise in generic drug consistency evaluation and the development of complex formulations, including peptides and modified-release injections. Listed on the Shanghai Stock Exchange, the company operates multiple specialized subsidiaries to support pharmaceutical clients globally in accelerating drug candidates from concept to market authorization.